STOCK TITAN

Aclaris Therapeutics, Inc. - $ACRS STOCK NEWS

Welcome to our dedicated page for Aclaris Therapeutics news (Ticker: $ACRS), a resource for investors and traders seeking the latest updates and insights on Aclaris Therapeutics stock.

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) is a leading clinical-stage biopharmaceutical company specializing in the development of innovative therapies for immuno-inflammatory diseases. Founded by dermatologists, Aclaris leverages its extensive expertise in dermatologic treatments to address significant unmet needs in both medical and aesthetic dermatology.

Aclaris operates primarily through two segments: therapeutics and contract research. The therapeutics segment focuses on identifying and developing novel therapies to treat immuno-inflammatory diseases. Key drug candidates in this segment include Zunsemetinib, an oral MK2 inhibitor, ATI-2138, an ITJ inhibitor, and ATI-1777, a topical JAK 1/3 inhibitor. The contract research segment generates revenue by offering laboratory services, which constitute a significant portion of the company’s revenue.

Recent milestones for Aclaris include the progression of ATI-2138 into Phase 2a proof-of-concept trials for T cell-mediated autoimmune diseases and the completion of enrollment for the ATI-1777 Phase 2b trial in atopic dermatitis. Preliminary data from these trials have shown promising results, paving the way for further clinical development. Aclaris has also announced partnerships with institutions like Washington University to explore additional therapeutic applications for its drug candidates.

Financially, Aclaris maintains a robust liquidity position. As of the end of 2023, the company holds approximately $181.9 million in cash, cash equivalents, and marketable securities, ensuring the capability to fund operations through 2025. Revenue generation is primarily driven by contract research services and strategic licensing agreements, such as the recent deal with Sun Pharmaceutical Industries, Inc., which grants exclusive rights under certain patents for the use of deuruxolitinib in treating alopecia areata and androgenetic alopecia.

Rhea-AI Summary

Aclaris Therapeutics (NASDAQ: ACRS) announced that Dr. Neal Walker, Interim President & CEO, will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference. The event will take place on June 11, 2024, at 11:20 AM ET in Miami, Florida.

The chat will be webcasted and accessible via the company's website, where it will be archived for at least 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.9%
Tags
conferences
-
Rhea-AI Summary

Aclaris Therapeutics reported its financial results for the first quarter of 2024 and provided a corporate update. The company is progressing ATI-2138 into a Phase 2a trial for atopic dermatitis. Aclaris also announced positive results for its various ITK inhibitor programs and highlighted financial data showing a decrease in net loss and revenue. The company anticipates lower cash expenditures in future quarters due to ongoing strategic reviews.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.96%
Tags
-
Rhea-AI Summary

Aclaris Therapeutics, Inc. (NASDAQ: ACRS) will announce its first quarter 2024 financial results on May 7, 2024. The company focuses on developing drug candidates for immuno-inflammatory diseases. A conference call will follow to provide a corporate update.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.82%
Tags
Rhea-AI Summary
Flare Therapeutics appoints Douglas Manion, a seasoned pharmaceutical executive, as the new Chief Executive Officer. Dr. Manion's extensive experience in drug development and leadership roles in biotechnology and pharmaceutical companies positions him well to drive Flare Therapeutics' growth and advance its clinical-stage pipeline. The company aims to revolutionize the field by targeting transcription factors to discover precision medicines for cancer and other diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary
Aclaris Therapeutics, Inc. announces financial results for Q4 and full year 2023, highlighting positive research and development updates. The company reported a net loss of $1.5 million in Q4 2023, with total revenue reaching $17.6 million. Aclaris had cash, cash equivalents, and marketable securities of $181.9 million as of December 31, 2023. The company is focused on advancing its drug candidates for immuno-inflammatory diseases and seeking development partners. Despite challenges like increased R&D expenses and intangible asset impairment charges, Aclaris remains optimistic about its future.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
-
Rhea-AI Summary
Aclaris Therapeutics, Inc. announced leadership changes and a strategic review of its business. Dr. Douglas Manion stepped down as CEO and President, with Dr. Neal Walker appointed as Interim CEO. The company also disclosed a preliminary unaudited cash position of approximately $182 million as of December 31, 2023. Aclaris is seeking a development and commercialization partner for its investigational drugs ATI-1777 and ATI-2138, with positive results from recent trials. The company plans to continue advancing discovery programs through its proprietary drug discovery platform, KINect®.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
25.54%
Tags
management
Rhea-AI Summary
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced top-line results from its Phase 2b study of ATI-1777, an investigational topical 'soft' JAK 1/3 inhibitor, in patients with atopic dermatitis. The trial achieved a statistically significant result in the primary efficacy endpoint at week 4, demonstrating response rates on par with existing market competition and a differentiated safety profile. The trial met the primary efficacy endpoint, showing a significant reduction in the Eczema Area and Severity Index (EASI) score at week 4 for patients treated with ATI-1777 2% BID compared to patients treated with the vehicle. A PK analysis showed minimal levels of exposure to ATI-1777, and it was well tolerated with no serious adverse events commonly associated with JAK inhibitors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.48%
Tags
-
Rhea-AI Summary
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announced the publication of Phase 2a trial results of ATI-1777 in moderate to severe atopic dermatitis (AD) in the peer-reviewed journal JID Innovations. The Phase 2b trial topline data is anticipated in January 2024. Aclaris also announced a reduction in workforce and several other corporate updates related to its drug development pipeline and workforce restructuring.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
-
Rhea-AI Summary
Aclaris Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: ACRS), has entered into an exclusive patent license agreement with Sun Pharmaceutical Industries, granting Sun Pharma exclusive rights to use deuruxolitinib to treat alopecia areata and androgenetic alopecia. The agreement includes an upfront payment of $15 million, regulatory and commercial milestones, and royalties.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
none
Rhea-AI Summary
Aclaris Therapeutics, Inc. (NASDAQ: ACRS) announces disappointing results from a Phase 2b study of zunsemetinib in patients with rheumatoid arthritis. Both 20mg and 50mg doses did not meet primary or secondary efficacy endpoints. Aclaris will discontinue further development of the ATI-450 program, including halting enrollment of the ongoing Phase 2a trial in psoriatic arthritis. The company plans to host a conference call and webcast to review the trial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-86.44%
Tags

FAQ

What is Aclaris Therapeutics, Inc. focused on?

Aclaris Therapeutics, Inc. is focused on developing novel therapies to address significant unmet needs in immuno-inflammatory diseases and dermatology.

What are the key drug candidates Aclaris is developing?

Aclaris' key drug candidates include Zunsemetinib (an oral MK2 inhibitor), ATI-2138 (an ITJ inhibitor), and ATI-1777 (a topical JAK 1/3 inhibitor).

What recent clinical trial milestones has Aclaris achieved?

Aclaris has progressed ATI-2138 into Phase 2a proof-of-concept trials for T cell-mediated autoimmune diseases and completed enrollment for the ATI-1777 Phase 2b trial in atopic dermatitis.

How does Aclaris generate revenue?

Aclaris generates revenue through its contract research segment by providing laboratory services and through strategic licensing agreements.

What was the recent licensing agreement with Sun Pharmaceutical Industries about?

Aclaris granted Sun Pharmaceutical Industries exclusive rights under certain patents for the use of deuruxolitinib to treat alopecia areata and androgenetic alopecia.

What is Aclaris' financial position as of the end of 2023?

As of the end of 2023, Aclaris had approximately $181.9 million in cash, cash equivalents, and marketable securities.

What partnerships does Aclaris have for clinical development?

Aclaris has partnerships with institutions like Washington University to explore additional therapeutic applications for its drug candidates.

What is the significance of ATI-2138's recent trial results?

ATI-2138 showed promising results in a Phase 1 multiple ascending dose trial, demonstrating potential for treating T cell-mediated diseases.

What is the focus of Aclaris' therapeutics segment?

The therapeutics segment focuses on identifying and developing novel therapies for immuno-inflammatory diseases.

What makes Aclaris unique in the biopharmaceutical industry?

Aclaris is unique due to its foundation by dermatologists and its focus on developing treatments for unmet needs in dermatology and immuno-inflammatory diseases.

Aclaris Therapeutics, Inc.

Nasdaq:ACRS

ACRS Rankings

ACRS Stock Data

80.53M
50.39M
2.78%
95.84%
6.89%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
WAYNE